Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mezagitamab - Takeda

Next Previous
Drug Profile

Mezagitamab - Takeda

Alternative Names: Anti-CD38 mAb; TAK-079

Latest Information Update: 05 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International
  • Developer Takeda
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; IgA nephropathy; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura; IgA nephropathy
  • Phase II Multiple myeloma; Myasthenia gravis
  • Phase I/II Systemic lupus erythematosus
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Jun 2026 Takeda plans a phase II trial for Renal transplant rejection in September 2026 (SC) (NCT07613359)
  • 28 Mar 2026 No recent reports of development identified for phase-I development in IgA-nephropathy(Adjunctive treatment) in Australia (SC, Injection)
  • 28 Mar 2026 No recent reports of development identified for phase-I development in IgA-nephropathy(Adjunctive treatment) in China (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top